

FORM PTO-1083
Mail Stop: Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450



Docket No.: 200.1133CON5

Date: July 10, 2007

3FV

In re application of: Benjamin Oshlack, et al.
Serial No.: 10/700,906
Filed: November 4, 2003
For: **TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS**

Sir:

Transmitted herewith is a **Supplemental Information Disclosure Statement (2 pages)** in the above-identified application.

- ☐ Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.
- ☐ Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.
- ☒ No fee for additional claims is required.
- ☐ A filing fee for additional claims calculated as shown below, is required:

- ☒ Also transmitted herewith are:
 - ☐ Petition for extension under 37 C.F.R. 1.136
 - ☒ Other: **Form PTO-1449 (1 page) with copies of the cited references.**

- ☒ Check(s) in the amount of **\$180.00** is/are attached to cover:
 - ☐ Basic filing fee
 - ☐ Petition fee under 37 C.F.R. 1.136
 - ☒ Other: Information Disclosure Statement Fee

- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.
 - ☐ Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.
 - ☒ Any patent application processing fees under 37 C.F.R. 1.17.
 - ☒ Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.


Robert J. Paradiso, Reg.No.41,240
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel: (212) 736-1940
Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service with sufficient postage as "first class mail" in an envelope addressed to Mail Stop: Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 10, 2007.
DAVIDSON, DAVIDSON & KAPPEL, LLC

BY: 
Oleg Ioselevich



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Humera N. SHEIKH Art Unit: 1615
Re: Application of: Benjamin OSHLACK, et al.
Serial No.: 10/700,906
Filed: November 4, 2003
For: **TAMPER-RESISTANT ORAL
OPIOID AGONIST
FORMULATIONS**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 10, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

S i r:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. 1.98(a)(2), a copy of each cited document is enclosed. If it is determined that a copy of any of the cited documents is missing, the Examiner is requested to contact the undersigned so that the missing copy may be forwarded.


It is respectfully requested that the documents listed on the accompanying Form PTO-1449 (1 page) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) before the mailing of "any of a final office action under § 1.311, a notice of allowance under

§ 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application,” and is accompanied by a fee in the amount of \$180.00. If it is determined that any additional fee is due or overpayment made, the Examiner is authorized to charge said fee or credit said overpayment to Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON5SERIAL NO.:
10/700,906

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262.
	AK	J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201
	AL	John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Programs," Clinical Pharmacology and Therapeutics, Vol. 15, Number 2, pp. 156-166, received for publication June 11, 1973
	AM	Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, Volume 16, Number 4, pp. 653-657; received for publication January 21, 1974
	AN	Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method For Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, Volume 21, Number 4, pp. 409-413; received for publication November 16, 1976
	AO	Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., Vol. 27, Number 4, pp. 492-501, received for publication September 15, 1979
	AP	Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, Vol. 260, No. 1, pp. 355-363, 1992
	AQ	Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130
	AR	
	AS	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.